Insulet Corporation

Equities

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 09:40:20 2024-03-28 am EDT 5-day change 1st Jan Change
170.3 USD +0.64% Intraday chart for Insulet Corporation +1.18% -22.03%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
US Equity Markets Close Higher Wednesday as Fed Holds Rates Steady MT
Insulet Names Ana Maria Chadwick Finance Chief MT
Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024 CI
Insulet Corporation Announces Chief Financial Officer Changes CI
3M Board Approves Healthcare Unit Spinoff -- Update DJ
Transcript : Insulet Corporation - Special Call
Insulet Says Trial Shows Omnipod 5 Insulin Delivery System Superior to Pump Therapy MT
Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) CI
Transcript : Insulet Corporation Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-05-2024 11:35 AM
Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes CI
Stocks in motion: Alphabet drops as Microsoft signs another AI partnership Our Logo
Barclays Trims Insulet Price Target to $213 From $214, Maintains Equal Weight Rating MT
Insulet forecasts weak annual revenue growth; shares drop RE
Insulet Q4 Adjusted Earnings, Revenue Increase; Q1, 2024 Revenue Outlook Set MT
Transcript : Insulet Corporation, Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (PODD) INSULET CORPORATION Posts Q4 EPS $1.40, vs. Street Est of $0.66 MT
Earnings Flash (PODD) INSULET CORPORATION Reports Q4 Revenue $509.8M, vs. Street Est of $461.1M MT
Insulet Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Insulet beats quarterly profit estimates on strong demand for insulin pumps RE
Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024 CI
MORNING BID AMERICAS-AI 'tipping point' sends Nvidia, Nasdaq, Nikkei north RE
Insulet's Omnipod 5 Receives CE Mark for Abbott FreeStyle Libre 2 Plus Integration MT
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking... Our Logo
UBS Raises Insulet Price Target to $211 From $175, Maintains Neutral Rating MT
Insulet Corporation Announces Board Changes CI
Chart Insulet Corporation
More charts
Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (95.6%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (4.4%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). By the end of 2022, the group will have 2 production sites located in the United States and in China. The United States accounts for 72.2% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
169.2 USD
Average target price
236.9 USD
Spread / Average Target
+40.05%
Consensus
  1. Stock
  2. Equities
  3. Stock Insulet Corporation - Nasdaq
  4. News Insulet Corporation
  5. Insider Trends: Insulet Insider Disposition Eases Back 90-Days of Buys